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Streptococcus pneumoniae resistant to penicillin and 
macrolides has become increasingly prevalent in all 
parts of the world, and newer fluoroquinolones (FQs) 
with improved Gram-positive activity have been 
introduced as alternative first-line therapy in com- 
munity-acquired lower respiratory tract infecti0ns.r 
So far, in Turkey, the incidence of high-level 
penicillin resistance in pneumococci is still low (3.9%), 
as confirmed in a national multicenter study; 2 however, 
here we report the first strain of S. pneumoniae, isolated 
from a bacteremic cancer patient, exhibiting a high level 
of resistance to all FQs. 
A 63-year-old male with small-cell lung cancer was 
hospitalized because of a febrile neutropenia episode 
after 7 days of his third course of chemotherapy. On the 
third day of hospitalization, S. pneumoniae grew in two 
consecutive bottles of blood culture taken before 
empirical antimicrobial therapy was started. Oral 
ciprofloxacin 500 mg b.i.d. for 10 days had been 
empirically prescribed for a non-neutropenic febrile 
episode occurring after his second course of chemo- 
therapy, 20 days previously. 
The isolate was susceptible to all antibiotics tested, 
except for FQs. MICs for penicillin G (0.016 mg/L), 
ampicillin (0.064 mg/L), co-amoxiclav (0.032/0.015 mg/L), 
cefuroxime (0.12 mg/L), cotrimoxazole (0.2Y4.75 mg/L), 
tetracycline (0.5 mg/L), erythromycin (0.047 mg/L), 
clarithromycin (0.015 mg/L), azithromycin (0.125 mg/L), 
moxifloxacin (6 mg/L), gatifloxacin (12 mg/L), trova- 
floxacin (12 mg/L), grepafloxacin (16 mg/L), levo- 
floxacin (16 mg/L), ofloxacin (32 mg/L) and ciprofloxacin 
(>32 mg/L) were determined by E test (AB Biodisk, 
Solna, Sweden) in Mueller-Hinton agar plus 5% sheep 
blood, following the manufacturer’s recommendations. 
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Because of the withdrawal of both trovafloxacin and 
grepafloxacin from the market in August 1999, following 
only 2 months of clinical use, at the time when the strain 
had been isolated, levofloxacin was the single ‘respir- 
atory’ FQ used clinically in Turkey for 1.5 years, together 
with earlier FQs such as ciprofloxacin and ofloxacin. We 
found that the isolate was resistant not only to available 
and withdrawn FQs, but also to newer ‘respiratory’ FQs 
(i.e. moxifloxacin and gatifloxacin) never marketed 
before in Turkey. This finding emphasizes the concern 
that S. pneumoniae may display cross-resistance 
between the older and the more recently introduced 
FQs. Chen et al3 found that isolates of S. pneumoniae 
with reduced susceptibility to ciprofloxacin (MIC 
24 mg/L), which had become resistant before the 
introduction of the Gram-positive respiratory FQs in 
Canada, were often non-susceptible to these newer 
agents as well. 
Taking into consideration the presence of high-level 
FQ resistance in our isolate, high-level FQ resistance is 
hereafter likely to be encountered in clinical isolates 
with sequential mutations in FQ targets4 rendering 
them resistant even to newer FQs. Prior exposure to 
FQs, such as the recent use of ciprofloxacin in our 
patient, can contribute to the selection of FQ-resistant 
strains, as was likely in recent observations on respir- 
atory tract infections caused by S. pneumoniae resistant 
to levofloxacin, irrespective of penicillin resistance.5,6 
Likewise, emergence of FQ-resistant viridans group 
streptococci in connection with the use of levofloxacin 
prophylaxis during neutropenia has been reported 
recently.7 
Although recent reports suggest that decreased 
susceptibility to FQs among pneumococci is associated 
with increasing numbers of FQ prescriptions3J no such 
systematic evaluation of FQ activity and the factors 
associated with reduced susceptibility has yet been done 
in Turkey. 
Also, in these reports, decreased susceptibility was 
most pronounced among those in the group above 65 
years of age, to which our patient belonged, suggesting 
a possible source of and reservoir for FQ-resistant 
pneumococci. 
Furthermore, there are areas of the world where 
resistant isolates have emerged, albeit in relatively low 
frequencies at the present time.s9 Although it might be 
inappropriate to extrapolate from one nation’s exper- 
ience to other nations, similar increases in both the 
prevalence and the degree of decreased susceptibility to 
FQs could be expected in Turkey, where liberal use 
of antimicrobials, including FQs, is common. More 
worrisome would be the potential for increased resis- 
tance of S. pneumoniae to even the latest FQs, as in the 
isolate reported here. 
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All FQs should now be used with greater care than 
in the past, because of the clonal dissemination potential 
of antibiotic-resistant S. pneumoniae, both across 
geographic borderslO and in institutional settings.li It 
may also be appropriate to consider routine testing of 
the susceptibility of respiratory S. pneumoniae isolates 
to FQs. 
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